Posted by Michael Wonder on 06 Dec 2018
Why regulators must move with the science if we’re to get innovative new treatments to patients more quickly
5 December 2018 - Professor Paul Workman, discusses the findings of the ICR's new drug access report, which asks how we can best harness advances in science to bring innovative drugs to patients.
One of the most rewarding moments for a cancer researcher is when you first get to see evidence coming through from clinical trials showing that patients are benefiting from a treatment which you helped to create.
We all work in cancer research to make a difference to patients, and knowing that your work can result in people living longer, and with an improved quality of life, is enormously motivating.
